Alkermes (ALKS) Free Cash Flow Growth (1y) (2011 - 2026)
Alkermes (ALKS) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.81 Bn | 32.07 Bn | 1.97 Bn | 10.34% |
| 3 | Zoetis | 32.47 Bn | 30.53 Bn | 1.62 Bn | -13.65% |
| 4 | Takeda Pharmaceutical | 27.55 Bn | 23.49 Bn | 4.39 Bn | 56.40% |
| 5 | United Therapeutics | 23.10 Bn | 20.95 Bn | 648.10 Mn | -5.85% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.31 Bn | 18.50 Bn | 1.16 Bn | -29.32% |
| 8 | Neurocrine Biosciences | 17.77 Bn | 16.46 Bn | 800.70 Mn | 166.91% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 44.93% |
| 10 | Alkermes | 8.75 Bn | 8.24 Bn | 331.33 Mn | -291.47% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -291.47% |
| Dec 31, 2025 | -5.83% |
| Sep 30, 2025 | 15.04% |
| Jun 30, 2025 | -1.25% |
| Mar 31, 2025 | 594.82% |
| Dec 31, 2024 | 100.23% |
| Sep 30, 2024 | -13.99% |
| Jun 30, 2024 | -32.57% |
| Mar 31, 2024 | 145.33% |
| Dec 31, 2023 | 1,104.42% |
| Sep 30, 2023 | 965.62% |
| Jun 30, 2023 | 1,779.21% |
| Mar 31, 2023 | -302.79% |
| Dec 31, 2022 | -140.17% |
| Sep 30, 2022 | -112.63% |
| Jun 30, 2022 | -146.29% |
| Mar 31, 2022 | 126.14% |
| Dec 31, 2021 | -63.88% |
| Sep 30, 2021 | 44.93% |
| Jun 30, 2021 | 276.63% |